Sabra Health Care REIT Delivers Solid Q1 Results Amid Sector Recovery

Sabra Health Care REIT (SBRA) reported first-quarter 2025 results that broadly met expectations, with Funds from Operations (FFO) of $0.36 per share aligning with analyst consensus. Revenue of $183.54 million exceeded estimates by $3.31 million, signaling resilience in its senior housing and skilled nursing portfolios. The quarter’s performance sets a positive tone for Sabra’s 2025 guidance, which calls for 4% FFO growth year-over-year.

Key Highlights from Q1 2025

• FFO per diluted share: $0.36 (up 12.5% from $0.32 in Q1 2024).
• Normalized FFO: $0.35 per share (a slight dip from $0.34 in Q1 2024 due to one-time adjustments).
• Revenue: $183.54 million, surpassing the $180.23 million consensus, driven by strong occupancy and rate growth in senior housing.
• Same-store senior housing Cash NOI: Jumped 16.9% year-over-year, reflecting improved tenant performance and operational efficiencies.

What Drives the Numbers?

The revenue beat and FFO stability stem from Sabra’s strategic focus on its senior housing segment, which has outperformed expectations. The 16.9% surge in same-store senior housing NOI underscores robust demand for senior living services, a trend accelerated by aging demographics and post-pandemic recovery in healthcare utilization.

Additionally, Sabra’s liquidity position remains robust, with $1.1 billion in available capital as of March 31, 2025. This includes $22.7 million in cash and $917.3 million in undrawn credit facilities, enabling the company to pursue acquisitions. For instance, the $7.8 million purchase of a senior housing campus phase and over $200 million in pipeline opportunities with high-7% initial yields signal confidence in future growth.

Navigating the Full-Year Outlook

Sabra’s 2025 guidance targets $1.43–$1.46 FFO per share, representing 4% growth over 2024. The company projects low to mid-teens Cash NOI growth for its same-store senior housing portfolio, with the first half of the year expected to outperform the second. This optimism is underpinned by its strong tenant covenant metrics, including EBITDARM coverage ratios exceeding 2x for skilled nursing and senior housing segments.

However, challenges persist. Rising interest rates and workforce availability pressures in healthcare could strain margins. Sabra’s net debt-to-EBITDA ratio of 5.19x remains manageable, but any further rate hikes may test its refinancing flexibility.

Dividend and Balance Sheet Stability

The board declared a $0.30 per share quarterly dividend, consistent with prior periods. With AFFO per share rising to $0.37 (up from $0.35 in Q1 2024), the dividend remains well-covered, reinforcing Sabra’s reputation as a reliable income generator.

Risks on the Horizon

• Regulatory Risks: Dependence on government reimbursements (e.g., Medicare/Medicaid) exposes Sabra to policy changes.
• Occupancy Volatility: While senior housing occupancy improved, skilled nursing facilities face ongoing headwinds from shifting patient preferences.
• Acquisition Pipeline Execution: Over $200 million in deals must close smoothly to meet growth targets.

Conclusion: A Steady Hand in a Recovering Sector

Sabra’s Q1 results affirm its position as a leader in senior housing real estate, with strong operational execution and a disciplined capital strategy. The 16.9% same-store NOI growth and robust liquidity provide a foundation for achieving its 2025 FFO targets. While macroeconomic risks linger, the REIT’s focus on high-yielding acquisitions and its BBB- credit rating (affirmed by Fitch) suggest stability.

Investors should monitor second-quarter FFO results for further confirmation of the growth trajectory. With a dividend yield of ~6.7% and a stock price near its 52-week high, Sabra remains a compelling play on the long-term demand for senior care infrastructure. For income-focused portfolios, SBRA’s blend of defensive cash flows and growth catalysts makes it a standout name in the healthcare REIT space.

Data sources: Sabra Health Care REIT Q1 2025 earnings release, supplemental disclosures, and analyst estimates.